Evidence map›Paper›PMID 34017377›Full record

ArticleAmerican journal of translational research2021

Network pharmacology-guided mechanism study uncovers inhibitory effect of Mahuang Decoction on lung cancer growth by impeding Akt/ERK signaling pathways.

Ya Pan, Yuhong Chen, Chunnuan Wu, Jun Ai, Yun Wang, Junrong Jia, Liren Liu

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Bioengineered · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ya PanDepartment of Gastrointestinal Cancer Biology, Tianjin Medical University Cancer Institute & Hospital Tianjin 300060, China.
Yuhong ChenNational Clinical Research Center for Cancer Tianjin 300060, China.
Chunnuan WuNational Clinical Research Center for Cancer Tianjin 300060, China.
Jun AiThe State Key Laboratory of Medicinal Chemical Biology (SKLMCB), Nankai University Tianjin 300071, China.
Yun WangNational Clinical Research Center for Cancer Tianjin 300060, China.
Junrong JiaNational Clinical Research Center for Cancer Tianjin 300060, China.
Liren LiuDepartment of Gastrointestinal Cancer Biology, Tianjin Medical University Cancer Institute & Hospital Tianjin 300060, China.
Tianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer (LC) ranks the leading cause of cancer-related death worldwide, due partially to the unsatisfactory therapeutic effect of the mainstream treatment. Alternatively, Chinese herb medicine (CHM) offers a bright perspective for treating complex diseases. Mahuang Decoction (MHD), a classic CHM formula, has been widely used in treating respiratory diseases in China for centuries, but its action mechanism has yet to be fully investigated. In this study, we first systemically explore the action mechanism of MHD by using network pharmacology and bioinformatic analysis tools, which uncovered a potential "new use of old drug" for MHD in cancer treatment. The therapeutic effect of MHD on LC was then validated by oral administration of MHD in the immunodeficient mice bearing xenografted LC tumors. To better understand the pharmacological activity of MHD against LC, we next constructed a drug/disease-target PPI network composed of 252 putative core therapeutic targets of MHD using Cytoscape. The subsequent enrichment analysis for these targets suggested that MHD could affect the apoptosis and cell cycle of LC cells via impeding Akt/ERK signaling pathways. Notably, these

Indexed as

Akt/ERK signaling pathwaysbioinformaticsChinese herb medicine (CHM)lung cancer (LC)Mahuang Decoction (MHD)network pharmacology

Identifiers

PMID34017377
PMCPMC8129243
OpenAlexW3160097347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.